0.7812
前日終値:
$0.762
開ける:
$0.76
24時間の取引高:
131.83K
Relative Volume:
0.66
時価総額:
$59.60M
収益:
$9.53M
当期純損益:
$-44.61M
株価収益率:
-0.8585
EPS:
-0.91
ネットキャッシュフロー:
$-38.32M
1週間 パフォーマンス:
-1.24%
1か月 パフォーマンス:
-20.66%
6か月 パフォーマンス:
-53.50%
1年 パフォーマンス:
-49.92%
Cue Biopharma Inc Stock (CUE) Company Profile
CUE を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CUE
Cue Biopharma Inc
|
0.7812 | 59.60M | 9.53M | -44.61M | -38.32M | -0.91 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-03-13 | 開始されました | Jefferies | Buy |
2023-06-26 | 再開されました | Oppenheimer | Outperform |
2022-11-21 | 開始されました | Piper Sandler | Overweight |
2022-01-13 | 開始されました | H.C. Wainwright | Buy |
2022-01-03 | 開始されました | Craig Hallum | Buy |
2020-11-24 | 開始されました | Berenberg | Buy |
2020-04-09 | 開始されました | Stifel | Buy |
2020-01-28 | 開始されました | BTIG Research | Buy |
2020-01-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Cue Biopharma Inc (CUE) 最新ニュース
Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia
Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa
Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals
Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN
Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus
Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology
Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq
Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma
Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech
Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard
Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter
Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India
Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia
Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus
Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus
Cue Biopharma Prices $20 Million Public Offering of Stock, Warrants - marketscreener.com
Boehringer Ingelheim and Cue Biopharma partner to develop next-g - GuruFocus
Cue Biopharma Announces Proposed Public Offering | CUE Stock New - GuruFocus
Cue Biopharma (CUE) Stock Dips Amid $20M Public Offering Announcement - GuruFocus
Cue Biopharma Prices About $20 Mln Public Offering - Nasdaq
Cue Biopharma Announces Pricing of Approximately $20 Million Pub - GuruFocus
Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789 - MarketScreener
$20M Capital Raise: Inside Cue Biopharma's Latest Strategic Financing Move - Stock Titan
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - The Manila Times
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - Benzinga
Boehringer, Cue Biopharma ink autoimmune therapy deal By Investing.com - Investing.com South Africa
Cue Biopharma inks deal with Boehringer Ingelheim By Investing.com - Investing.com South Africa
Cue Biopharma launches public stock offering By Investing.com - Investing.com Canada
Cue Biopharma launches public stock offering - Investing.com Australia
Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments - MarketScreener
Cue Biopharma inks deal with Boehringer Ingelheim - Investing.com
Boehringer, Cue Biopharma ink autoimmune therapy deal - Investing.com
Form 424B5 Cue Biopharma, Inc. - StreetInsider
Cue Biopharma Announces Proposed Public Offering - The Manila Times
Cue Biopharma to Host Business Update Call and Webcast - Enidnews.com
Boehringer Ingelheim and Cue Biopharma partner to develop - GlobeNewswire
Major Biotech Deal: Cue Biopharma Secures $357M Partnership for Revolutionary Autoimmune Treatment - Stock Titan
‘Buy These Two Chip Stocks Ahead of a Recession,’ Says Citi - The Globe and Mail
S&P 500 jumps 1.8% as Wall Street closes a chaotic and historic week - The Globe and Mail
Can Spotify’s (SPOT) Ad Business Hit the Right Notes in 2025? - The Globe and Mail
Seeking High Dividend Yield? Earn 9.6% from This Energy Stock Now. - The Globe and Mail
EXL Schedules First Quarter 2025 Financial Results Conference Call - The Globe and Mail
Will Tariffs Destroy This Clothing Giant? - The Globe and Mail
United Community Banks, Inc. Announces Date for First Quarter 2025 Earnings Release and Conference Call - The Globe and Mail
Vision Marine Technologies Strengthens Innovation with New Patent Filing for Secure Vessel Connectivity - The Globe and Mail
Cue Biopharma Inc (CUE) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):